Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells.
Peripheral blood cells from nine patients with B-chronic lymphocytic leukemia (B-CLL) were treated in vitro with bryostatin 1 (a macrocyclic lactone derived from a marine invertebrate). Like the phorbol ester 12-0-tetradecanoyl-phorbol 13-acetate (TPA), bryostatin 1 activates protein kinase C (PKC), which plays a central role in the phosphatidylinositol signal transduction pathway. The effects of bryostatin 1 alone and in combination with TPA or with the calcium mobilizing ionophore A23187 were assessed by morphological appearance, cell adherence and aggregation, RNA and DNA synthesis, and immunoglobulin (Ig) production. While eight of nine B-CLL cultures remained proliferatively inert, bryostatin 1 could effectively trigger activation and differentiation of B-CLL cells in all cases as inferred by the induction of morphological changes, RNA synthesis, and monotypic Ig production. Addition of calcium ionophore A23187 to bryostatin 1-exposed cells resulted in significantly increased values for RNA synthesis and Ig production and in the acquisition of plasmacytoid morphology. Bryostatin 1 and the dual signal of bryostatin 1 plus A23187 mimicked the stimulatory action of TPA and the combination of TPA plus A23187, respectively. Overall, bryostatin 1 was less active than equivalent concentrations of TPA. This lesser efficacy may, however, reflect a quantitative rather than qualitative difference. Bryostatin 1 partially antagonized TPA-mediated effects on B-CLL cells suggesting different modes of action by the two activators. These studies indicate that bryostatin 1 has effective differentiation-inducing properties on B-CLL cells that can differentiation-inducing properties on B-CLL cells that can be accentuated by a calcium ionophore.
Drexler
H G
HG
Department of Haematology, Royal Free Hospital School of Medicine, Hampstead, London.
Gignac
S M
SM
Jones
R A
RA
Scott
C S
CS
Pettit
G R
GR
Hoffbrand
A V
AV
D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001402:B-Lymphocytes / Q000166:cytology / Q000276:immunology; D014408:Biomarkers, Tumor / Q000032:analysis; D054713:Bryostatins; D000001:Calcimycin / Q000494:pharmacology; D002448:Cell Adhesion / Q000187:drug effects; D002449:Cell Aggregation / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects*; D004273:DNA, Neoplasm / Q000096:biosynthesis; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000096:biosynthesis; D007783:Lactones / Q000494:pharmacology*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000473:pathology*; D018942:Macrolides; D008297:Male; D008875:Middle Aged; D012334:RNA, Neoplasm / Q000096:biosynthesis; D011947:Receptors, Antigen, B-Cell / Q000032:analysis; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000166:cytology* / Q000187:drug effects
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D054713:Bryostatins; D004273:DNA, Neoplasm; D007136:Immunoglobulins; D007783:Lactones; D018942:Macrolides; D012334:RNA, Neoplasm; D011947:Receptors, Antigen, B-Cell; D000001:Calcimycin; C046785:bryostatin 1; D013755:Tetradecanoylphorbol Acetate